Literature DB >> 11491260

Endovascular grafting of traumatic aortic aneurysms in contaminated fields.

S Krämer1, R Pamler, H Seifarth, H J Brambs, L Sunder-Plassmann, J Görich.   

Abstract

PURPOSE: To evaluate the potential of endovascular stent-grafts to treat traumatic aortic lesions in contaminated areas.
METHODS: Four patients (3 women; ages 26-78 years) underwent stent-grafting to repair an aortic rupture sustained in a motorcycle accident, aortic lacerations secondary to surgical treatment of spondylitis in 2 patients, and an aortobronchial fistula following surgical thoracic aortic repair 10 years earlier. Stent-grafts (2 Corvita, 1 Talent, and 1 Vanguard) were placed endoluminally into the infected areas via a transfemoral approach. Follow-up included erythrocyte sedimentation rate, white blood count, C-reactive protein, blood cultures, and computed tomography (CT).
RESULTS: The stent-grafts were successfully placed in all cases and excluded the aortic lesion. Under supportive antibiotic therapy, inflammation parameters returned to normal. CT imaging showed no evidence of paraprosthetic infection, nor were there any other complications over a follow-up that ranged from 3 to 34 months.
CONCLUSIONS: Endovascular therapy may be an alternative in the acute management of aortic ruptures in the setting of infection. Long-term results are required for definitive evaluation of the method.

Entities:  

Mesh:

Year:  2001        PMID: 11491260     DOI: 10.1177/152660280100800305

Source DB:  PubMed          Journal:  J Endovasc Ther        ISSN: 1526-6028            Impact factor:   3.487


  2 in total

1.  Thoracic aortic and great vessel trauma and its management.

Authors:  Simon J McPherson
Journal:  Semin Intervent Radiol       Date:  2007-06       Impact factor: 1.513

2.  Endovascular treatment of an open cervical fracture with carotid artery tear.

Authors:  Misha Witz; Reuven Gepstein; Haim Paran; Ali Shnaker; Jonathan Lehmann; Igal Gryton; Shay Shabat
Journal:  Eur Spine J       Date:  2006-07-21       Impact factor: 3.134

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.